Vertex (VRTX) Orkambi Briefing Docs 'Positive Overall', Baird Says
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
UPDATE: Vertex Pharma's (VRTX) Orkamibi Recommended for Approval by FDA Panel
May 12, 2015 3:42 PM EDT(Updated - May 12, 2015 3:46 PM EDT)
Vertex Pharma (NASDAQ: VRTX) Orkamibi Recommended for Approval by FDA Panel. According to Bloomberg, the panel vote was 12-1.
Previously, the FDA panel said Orkambi is safe to treat cystic fibrosis and that it couldn't determine if Lumacaftor contributes positively to Orkambi combo.
... MoreVertex Pharma (VRTX) Shares Halted Ahead of FDA Advisory Committee Meeting
May 12, 2015 7:31 AM EDTVertex Pharma (NASDAQ: VRTX) shares were halted for news ahead of an FDA advisory committee meeting on Orkambi.
... MoreRBC Comments on Vertex (VRTX) Following Orkambi Briefing Docs
May 8, 2015 10:03 AM EDTRBC Capital maintained an Outperform rating on Vertex (NASDAQ: VRTX) with a price target of $130. Shares weakened after the FDA posted Orkambi briefing docs, although they have since recovered. Analyst Michael J. Yee called the decline a buying opportunity.
Yee explained, "At first glance topics appear obvious: 1) asking on the magnitude of benefit; and 2) and comment on efficacy... More
Vertex Pharma (VRTX) on Watch After FDA Posts Briefing Docs for Orkambi to Treat CF
May 8, 2015 8:03 AM EDTThe FDA posted briefing docs related to Vertex Pharma's (NASDAQ: VRTX) lumacaftor/ivacaftor (Orkambi) combination oral tablets for the treatment of cystic fibrosis.
... More